weight loss drug prescriptions semaglutide tirzepatide q3 2024 data GLP-1 RA prescription trends: January 2018 – December The Multi-Sector Impacts of GLP-1RA

Stomach-related side effects may also occur with tirzepatide, especially when treatment begins or the dose changes

Weight loss injections, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy, Ozempic) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro), have transformed obesity management in recent years

The choice between injection and oral tirzepatide often depends on patient comfort level, lifestyle factors, and individual response patterns

Body composition tools like bioelectrical impedance analysis have significant error margins, particularly for lean mass measurement